Anavex posts mid-stage biomarker data for lead candidate
koto_feja/iStock via Getty Images

On Tuesday, Anavex Life Sciences (NASDAQ:AVXL), a clinical-stage biotech focused on treatment for CNS disorders, announced Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinsonâs Disease Dementia (PDD) study.
The data to be presented at an ongoing medical conference on neurological disorders included results on MDS-UPDRS, a rating scale developed to assess various aspects of Parkinsonâs disease.
Compared to placebo, the patients treated with a high oral once-daily dose of ANAVEX2-73 had their MDS-UPDRS total score improved significantly by -14.51 (p=0.034), according to Anavex (AVXL). Implying a relative improvement of 18.9% over 14 weeks, the company said that the improvement was âclinically relevant.â Anavex (AVXL) is trading ~11% higher in the pre-market currently.
"ANAVEX2-73 (blarcamesine) demonstrated dose-dependent efficacy for both motor impairment (MDS-UPDRS) and cognition (CDR system), which correlated with SIGMAR1 mRNA as a pharmacodynamic biomarker, respectively,â Chief Executive, Christopher U Missling, noted.
 âThese results support continued development of ANAVEXÂ®2-73 in Parkinsonâs disease and Parkinsonâs disease dementia,â as well as its trials in Rett syndrome and Alzheimerâs disease, he added.
Read: In January, biotech companies focused on Alzheimerâs disease fell after the Centers for Medicare & Medicaid Services (CMS) proposed to limit the coverage for Biogenâs (NASDAQ:BIIB)
Alzheimerâs therapy, Aduhelm.